Medical Licensing (MD/DO) · Independent exam preparation
Infectious Disease Certification Examination Study Guide
Develop infection diagnosis, resistance-guided treatment, HIV care, prevention, and critical care reasoning through 60 concepts, 20 clinical questions, and 20 flashcards.
By CertMedbry · Updated 18 October 2026
Distinguish colonization from infection, interpret discordant tests, select treatment according to resistance mechanism and infection site, and recognize emergencies requiring source control or supportive care. This selective guide develops clinical decisions across all ten domains of ABIM's January 2026 Infectious Disease Certification Examination blueprint. The complete official outline at https://www.abim.org/media/vikhznzl/infectious-disease-cert.pdf defines the full examination scope, including organisms, syndromes, pharmacology, and host conditions beyond these examples.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification examination does this guide address?
The Infectious Disease Certification Examination administered by the American Board of Internal Medicine. The listing label 'ABIM - Subspecialty in Infectious Disease' maps to this initial certification examination. Board certification and medical licensure are separate: holding an appropriate medical license is a certification prerequisite, while passing this examination is one component of ABIM certification requirements.
How many questions are administered, and which questions count?
The January 2026 blueprint describes up to 240 single-best-answer multiple-choice questions. Approximately 40 are new questions that do not count toward the score. These are approximate administration figures rather than a guarantee of an identical scored-question count for every examination.
Infectious Disease Blueprint — Certification Examination (CERT), January 2026
How long is the examination?
ABIM describes an examination day of approximately ten hours divided into four sessions, each containing up to sixty multiple-choice questions. This does not mean ten hours of uninterrupted question-answering time.
ABIM — Register, Prepare and Take Your Subspecialty Certification Exam: Infectious Disease
What item styles can appear?
Most questions present clinical scenarios and ask for a single best answer. Supporting material may include photographs, radiographs, electrocardiograms, heart or lung sound recordings, and other media. Tasks include diagnosis, test interpretation, treatment, risk assessment, and application of pathophysiology.
Infectious Disease Blueprint — Certification Examination (CERT), January 2026
Which blueprint version applies?
This guide uses the January 2026 certification blueprint identified by ABIM's certification blueprint index. January 2026 is its stated revision date; the document does not state a separate effective date. The official outline remains the full examination scope.
ABIM — Blueprints · Infectious Disease Blueprint — Certification Examination (CERT), January 2026
Does the announced expanded blueprint replace this outline?
ABIM's announced schedule places infectious disease diplomate review in fall 2026, expanded blueprint publication in January 2028, and certification-examination implementation in fall 2028. That planned outline does not replace the January 2026 certification blueprint used here. Maintenance-of-certification assessment blueprints are listed separately.
How is content weighted?
Official weights are Bacterial Diseases 27%; Human Immunodeficiency Virus (HIV) Infection 15%; Antimicrobial Therapy 9%; Viral Diseases 7%; Travel and Tropical Medicine 5%; Fungi 5%; Immunocompromised Host (Non-HIV Infection) 5%; Vaccinations 4%; Infection Prevention and Control 5%; and Internal Medicine and Non-Infectious Syndromes 18%. This guide allocates 14, 10, 7, 4, 3, 3, 3, 2, 3, and 11 concepts respectively. Each practice set allocates 5, 3, 2, 1, 1, 1, 1, 1, 1, and 4 items respectively. Small sets cannot reproduce every official percentage exactly.
Infectious Disease Blueprint — Certification Examination (CERT), January 2026
How should these practice materials be used?
Use the twenty original four-option questions as single-best-answer learning drills and the twenty flashcards for active recall. They do not reproduce secure ABIM questions, simulate every possible media format, or predict a passing result. Clinical references support the teaching recommendations; the ABIM blueprint establishes examination scope.
Infectious Disease Blueprint — Certification Examination (CERT), January 2026
These independently authored educational materials address initial infectious disease subspecialty board certification. They are not official ABIM examination questions or an ABIM-endorsed product.
Outline used: ABIM Infectious Disease Certification Examination blueprint, January 2026, currently linked by ABIM and verified on 2026-10-09. The workbook label 'ABIM - Subspecialty in Infectious Disease' maps to this initial subspecialty certification examination; the assigned slug is preserved. The PDF states its revision month but does not specify a separate effective date.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Bacterial Diseases27%
1.When should asymptomatic bacteriuria be treated or left untreated?
Asymptomatic bacteriuria means bacteria are present in urine without symptoms attributable to urinary infection, regardless of pyuria. Diabetes does not establish a treatment benefit. Avoid screening and treatment in a nonpregnant patient unless an established exception applies. Pregnancy and endoscopic urologic procedures expected to traumatize mucosa justify screening and treatment. Before the relevant procedure, obtain a urine culture and select targeted therapy because instrumentation through infected urine can precipitate postoperative sepsis.
Apply it
Withhold antibiotics for an asymptomatic woman with diabetes and E. coli in a routine culture. Treat bacteriuria before transurethral prostate resection.
Common pitfall: Pyuria and a high colony count do not establish symptomatic infection. Routine nonurologic surgery, including prosthetic joint implantation, does not create the urologic procedural exception.
IDSA 2019 Guideline for the Management of Asymptomatic Bacteriuria
3.How do increased-risk features guide cardiac evaluation in Staphylococcus aureus bacteremia?
The 2026 IDSA/ESCMID consensus identifies community-onset bacteremia, cultures positive at least forty-eight hours after the first positive sample, and an intracardiac device as key increased-risk features. Perform TTE routinely in adults. Despite a negative TTE, TEE is suggested for an intracardiac device, predisposing valve disease, persistent cultures, embolic events, or multiple noncontiguous infectious foci. Community onset or injection drug use supports consideration of TEE according to the complete clinical assessment.
Apply it
A prosthetic valve maintains concern for endocarditis despite a negative transthoracic study and improving fever.
Common pitfall: Risk features guide investigation rather than independently proving endocarditis. Risk changes during care, and an extracardiac source does not exclude secondary valve or device infection.
4.Why cannot an infection test establish active tuberculosis?
An interferon-gamma release assay or tuberculin skin test detects an immune response consistent with tuberculosis infection; it does not distinguish latent infection from active disease. A positive result requires clinical evaluation, including symptoms and chest imaging, before preventive treatment is considered. A negative result does not reliably exclude disease in a symptomatic or immunocompromised patient. Suspected pulmonary disease requires respiratory microbiology rather than repeated immune testing as the principal diagnostic strategy.
Apply it
Continue respiratory testing in a patient with weight loss, cough, and an upper-lobe cavity despite a negative interferon-gamma release assay.
Common pitfall: A latent-infection regimen can undertreat active disease. Neither a positive nor a negative immune-response test replaces the evaluation for disease.
5.How should pulmonary tuberculosis microbiology be assembled?
Obtain at least three consecutive sputum specimens eight to twenty-four hours apart, including an early-morning specimen, in an appropriate airborne-controlled collection setting. Acid-fast microscopy rapidly detects organisms but cannot distinguish tuberculosis from nontuberculous mycobacteria. Nucleic acid amplification rapidly identifies tuberculosis-complex material and selected resistance markers. Culture specimens regardless of smear findings to recover the organism and support identification and susceptibility testing.
Apply it
A molecular rifampin-resistance marker should prompt appropriate management and further resistance assessment while cultures continue. Obtain genuine respiratory secretions rather than repeatedly submitting saliva.
Common pitfall: A negative smear does not exclude disease. A molecular resistance result describes the targets tested, rather than the organism's complete susceptibility profile.
7.How should follow-up blood cultures be obtained in adult Staphylococcus aureus bacteremia?
The 2026 consensus suggests obtaining at least two follow-up blood-culture sets forty-eight hours after sampling the first positive culture, then repeating one or two sets every twenty-four to forty-eight hours until negative. A set comprises an aerobic and an anaerobic bottle. Positive cultures at or beyond forty-eight hours increase concern for a deep or endovascular focus and require diagnostic and source-control reassessment.
Apply it
Persistent positivity despite an active antibiotic should trigger evaluation of catheters, implanted material, cardiac involvement, and symptoms suggesting metastatic infection.
Common pitfall: Defervescence does not document bloodstream clearance. Clearance is the first negative culture after which no subsequent S. aureus-positive culture is documented; a transient negative result followed by renewed positivity does not establish clearance.
8.How should discordant reverse-sequence syphilis tests be resolved?
When an initial treponemal immunoassay is reactive but the quantitative nontreponemal test is nonreactive, perform a different treponemal assay, preferably using different antigens. A positive second treponemal test can reflect previously treated infection, untreated infection, or early infection. Treatment history and recent exposure determine management. If the second treponemal test is negative and clinical and epidemiologic probability are low, additional evaluation or treatment is generally unnecessary.
Apply it
Request TP-PA after a reactive screening immunoassay and nonreactive RPR, and review previous treatment records before deciding on treatment.
Common pitfall: A negative RPR does not always exclude syphilis, and persistent treponemal reactivity does not automatically require retreatment.
9.What constitutes a meaningful change in a syphilis titer?
A clinically significant nontreponemal titer change is fourfold, equivalent to two serial dilutions, when the same test method is used. A decline from 1:32 to 1:8 is fourfold; a decline from 1:32 to 1:16 is only twofold. Interpret direction and timing in relation to treatment, disease stage, symptoms, and exposure. Treponemal tests often remain reactive after successful treatment and should not measure therapeutic response.
Apply it
An RPR increase from 1:8 to 1:32 warrants reassessment for reinfection or treatment failure, including exposure history and previous treatment adequacy.
Common pitfall: RPR and VDRL titers are not interchangeable. Persistent treponemal positivity alone does not demonstrate active disease or failed therapy.
10.When does suspected neurosyphilis warrant cerebrospinal fluid evaluation?
Neurologic findings such as cranial nerve dysfunction, meningitis, stroke, altered mental status, or loss of vibration sense warrant cerebrospinal fluid evaluation in a patient with reactive syphilis serology. Diagnosis integrates the examination, serum tests, and CSF findings. A reactive CSF-VDRL without blood contamination is highly specific, but sensitivity is limited. A negative CSF-VDRL therefore does not exclude neurosyphilis when clinical and inflammatory CSF findings remain convincing.
Apply it
Obtain CSF studies for a patient with reactive serology, meningitic symptoms, and a new cranial neuropathy.
Common pitfall: A high serum titer alone does not routinely justify lumbar puncture in a neurologically normal patient. Conversely, a negative CSF-VDRL cannot override strong clinical evidence.
11.How do evaluation and clearance determine Staphylococcus aureus bacteremia treatment duration?
Fourteen days is suggested for low-risk adults without a deep-seated or metastatic focus after appropriate evaluation. Some increased-risk adults also qualify when symptoms resolve and tailored evaluation with ongoing assessment reveals no deep focus. Confirmed deep infection, retained infected material, incomplete testing, or persistent concern can require longer treatment. Initial risk classification guides investigation but does not independently establish the final treatment duration.
Apply it
Count treatment from documented blood-culture clearance. When source control occurs after clearance, the date of focus removal may instead serve as the start date.
Common pitfall: Finding one focus does not exclude additional noncontiguous sites. Defervescence alone cannot establish clearance or justify a short course without adequate diagnostic assessment.
12.When is erythema migrans a clinical diagnosis?
A compatible expanding erythematous lesion after plausible exposure in a Lyme-endemic area supports a clinical diagnosis of erythema migrans. Early antibody testing may be negative before the immune response becomes detectable, so a classic presentation should not wait for serologic confirmation. An atypical lesion requires a different strategy, often acute and convalescent antibody testing. The useful distinction is an evolving compatible lesion in context rather than a perfectly target-shaped rash.
Apply it
Treat a compatible enlarging lesion after endemic exposure despite an early negative antibody test.
Common pitfall: A small immediate bite-site reaction is not automatically erythema migrans. Absence of central clearing does not exclude a compatible expanding lesion.
13.Which tick bites qualify for Lyme prophylaxis?
A high-risk exposure requires an identified Ixodes vector, exposure in a highly endemic area, and attachment for at least thirty-six hours. Administer prophylaxis within seventy-two hours after tick removal. When these criteria are met and doxycycline is appropriate, the adult regimen is doxycycline 200 mg orally once. If risk cannot confidently be classified as high, observation and symptom education are appropriate.
Apply it
An Ixodes tick attached for approximately forty-eight hours in a highly endemic area was removed yesterday. Assess doxycycline suitability and administer prophylaxis within the remaining window.
Common pitfall: Assessment within seventy-two hours is insufficient if administration occurs later. Established erythema migrans requires a treatment course rather than a prophylactic dose.
14.When should imaging extend beyond the initially suspected source of Staphylococcus aureus bacteremia?
Begin with history, serial examinations, follow-up cultures, echocardiography, and symptom-directed imaging. New back pain can justify spinal MRI, while a swollen joint requires focused assessment. In increased-risk bacteremia with an unknown focus after an appropriate initial evaluation, the 2026 consensus suggests whole-body imaging such as FDG-PET/CT or combinations of imaging modalities targeting likely infectious sites. The choice depends on clinical condition and availability.
Apply it
Persistent bacteremia without a source after cardiac and symptom-directed evaluation warrants a broader search for occult infection.
Common pitfall: Whole-body imaging does not replace basic evaluation. Evidence for PET/CT is mainly observational, so detection of additional foci should be distinguished from a proven mortality benefit.
15.Which findings make ehrlichiosis a priority diagnosis?
Fever, headache, and malaise after plausible tick exposure become particularly suggestive when leukopenia, thrombocytopenia, and elevated aminotransferases occur together. Rash is absent in many adults, and patients may not recall a bite. Early normal blood counts do not exclude infection. Severe disease can include neurologic involvement, respiratory failure, shock-like illness, and other organ dysfunction, particularly when recognition and treatment are delayed.
Apply it
Prioritize ehrlichiosis in a gardener with summer fever, cytopenias, and aminotransferase elevation despite absent rash and no remembered tick attachment.
Common pitfall: The laboratory pattern supports diagnostic priority rather than proving the organism. Absence of a rash or a recalled bite should not outweigh a compatible exposure, season, and evolving clinical syndrome.
16.How should resistant gram-negative colonization be distinguished from infection?
Isolation of a resistant gram-negative organism does not by itself establish disease. Determine whether the specimen, new clinical findings, imaging, and host response support infection at that site. Respiratory and wound isolates in medically complex patients may represent persistent colonization. Resistance changes treatment options once infection is established; it does not create an indication for treatment. Unnecessary therapy exposes patients to toxicity and further resistance selection.
Apply it
A chronically ventilated patient with unchanged oxygen requirements and no new infiltrate should not automatically receive treatment for a resistant tracheal isolate.
Common pitfall: An alarming susceptibility report can distract from an absent syndrome. Previous colonization can nevertheless inform empiric selection when a genuine new infection develops.
IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
Human Immunodeficiency Virus (HIV) Infection15%
2.How should a low-positive HIV RNA result be interpreted during suspected acute infection?
Detectable plasma HIV RNA with negative or indeterminate antibody findings can identify acute infection before seroconversion. Even a low-positive RNA result can represent very early infection, although an isolated low result can occasionally be false positive. Repeat quantitative RNA testing on a new specimen and complete the appropriate serologic evaluation. Exposure timing and compatible symptoms determine how urgently the result must be resolved.
Apply it
A patient with a recent exposure, febrile rash illness, nonreactive screening test, and low detectable RNA needs prompt repeat sampling and clinical assessment rather than reassurance.
Common pitfall: Do not require the extremely high viral load often associated with acute HIV before considering the diagnosis. Conversely, avoid treating one ambiguous low-level result as independently conclusive.
17.When should acute HIV be investigated despite a negative screening test?
Acute HIV can cause fever, rash, pharyngitis, lymphadenopathy, or a nonspecific mononucleosis-like illness before antibody tests become reactive. When exposure timing and symptoms create meaningful suspicion, obtain plasma HIV RNA alongside the appropriate antigen-antibody evaluation. RNA can become detectable earlier than a fully developed antibody response. A negative initial screen therefore does not close the diagnosis during the window period.
Apply it
A patient with fever, sore throat, and generalized rash shortly after sexual exposure needs HIV RNA testing despite a nonreactive initial screen.
Common pitfall: The syndrome is not specific for HIV. Diagnose through appropriately timed virologic and serologic testing rather than symptoms alone or reassurance from one early screen.
18.How should resistance testing and prior cabotegravir exposure guide rapid ART?
Obtain baseline resistance specimens before ART when possible, but do not routinely delay appropriate treatment for the report. Standard genotyping includes reverse transcriptase and protease. HIV acquisition during or after long-acting cabotegravir prevention also requires integrase testing. Pending that result, use boosted darunavir with TAF or TDF plus emtricitabine or lamivudine; avoid empiric integrase-based ART until susceptibility is established.
Apply it
For acute HIV after cabotegravir prevention, obtain an integrase-inclusive genotype and begin an appropriate boosted-darunavir-based regimen while arranging review of the results.
Common pitfall: Rapid initiation includes baseline sampling and subsequent result review. Prior cabotegravir changes the empiric regimen because integrase resistance may have been selected, even when treatment is beginning promptly.
19.How should HBV status be established before selecting or simplifying HIV treatment?
Assess HBsAg, anti-HBs, and total anti-HBc together to distinguish current HBV infection, vaccine immunity, previous natural infection, and patterns requiring clarification. In a person with HIV, HBV status affects ART selection because some antiretrovirals suppress both viruses. HBsAg positivity requires an HBV treatment assessment, while isolated anti-HBc can require additional evaluation for occult infection or previous infection with waning antibody.
Apply it
Before changing a tenofovir-containing regimen to an HIV regimen without HBV activity, review the complete HBV serologic pattern and any available HBV DNA results.
Common pitfall: An HIV-suppressive regimen is not automatically adequate HBV treatment. Anti-HBs alone cannot establish the complete history without considering core antibody, surface antigen, and relevant treatment records.
NIH — Hepatitis B Virus Infection: Adult and Adolescent Opportunistic Infections · CDC — Clinical Testing and Diagnosis for Hepatitis B
20.Why is ART delayed in cryptococcal meningitis?
In HIV-associated CNS cryptococcosis, restoring immune responses too early can provoke dangerous inflammation within the confined intracranial compartment. NIH guidance generally defers ART for four to six weeks after antifungal treatment begins. This exception does not delay antifungal therapy or management of intracranial pressure. The decision balances fungal control, neurologic stability, and immune reconstitution risk rather than applying a same-day ART rule to every opportunistic infection.
Apply it
Begin antifungal treatment and pressure management immediately, then plan ART within the recommended delayed interval.
Common pitfall: A very low CD4 count does not erase this exception. Conversely, this CNS-specific timing should not be extended automatically to every opportunistic infection.
NIH — Cryptococcosis: Adult and Adolescent Opportunistic Infections
21.How should raised pressure in cryptococcal meningitis be managed?
Measure lumbar opening pressure and treat symptomatic elevation with CSF drainage. Drain enough to reduce pressure by at least 50% or normalize it below 20 cm CSF. With ongoing symptoms, repeat therapeutic lumbar punctures at least daily until symptoms and signs consistently improve and pressure normalizes. Strongly consider an early repeat procedure even when initial symptoms are limited or opening pressure is not elevated. Persistent pressure problems may require a drain or shunt.
Apply it
Headache, blurred vision, and opening pressure of 36 cm CSF require drainage, a documented pressure response, and reassessment.
Common pitfall: Pressure can worsen despite microbiologic improvement. Mannitol, acetazolamide, and routine corticosteroids do not replace drainage.
NIH — Cryptococcosis: Adult and Adolescent Opportunistic Infections
22.How should neurologic deterioration during cryptococcal treatment be reassessed?
Recurrent headache or neurologic decline can reflect raised intracranial pressure, persistent or relapsed infection, or immune reconstitution inflammation. Reassess the examination, treatment adherence, antifungal exposure, ART timing, and CSF opening pressure. CSF culture helps determine whether viable Cryptococcus remains present. Cryptococcal antigen can remain detectable after successful treatment and cannot independently distinguish microbiologic relapse from immune-mediated inflammation.
Apply it
A patient who worsens after ART initiation needs renewed pressure assessment and microbiologic evaluation rather than an automatic diagnosis of immune reconstitution inflammatory syndrome.
Common pitfall: The timing after ART is suggestive but not definitive. Persistent antigen positivity does not itself prove treatment failure, and apparent inflammatory deterioration does not exclude an uncontrolled pressure problem.
NIH — Cryptococcosis: Adult and Adolescent Opportunistic Infections
23.Which treatment backbone addresses both HIV and chronic HBV?
A fully suppressive ART regimen should generally include TAF or TDF together with emtricitabine or lamivudine when appropriate, supplying two HBV-active components. Emtricitabine or lamivudine as the only HBV-active drug encourages HBV resistance. Selection must also consider renal suitability, previous treatment, and the remaining drugs needed for complete HIV suppression. Suppressing one virus does not establish that the other is adequately treated.
Apply it
For an HBsAg-positive patient beginning ART, select an appropriate complete HIV regimen that also supplies recommended HBV activity rather than adding lamivudine alone for hepatitis B.
Common pitfall: Two HBV-active agents do not independently constitute a complete HIV regimen. Undetectable HBV DNA during treatment represents suppression rather than reliable eradication.
NIH — Hepatitis B Virus Infection: Adult and Adolescent Opportunistic Infections
24.What limits the use of entecavir in HIV/HBV coinfection?
When tenofovir cannot be used, entecavir can treat HBV only alongside fully suppressive ART. Its weak anti-HIV activity can select the HIV M184V mutation if HIV replication is not controlled. Entecavir is not recommended for known or suspected lamivudine-resistant HBV because the resistance background reduces its reliability. Previous lamivudine exposure should prompt assessment, but exposure alone does not prove resistance.
Apply it
Before selecting entecavir, verify the HIV regimen's suppressive activity and review prior HBV treatment response, available resistance information, and the reason tenofovir is unsuitable.
Common pitfall: Entecavir is not an HIV treatment substitute. Increasing its dosage does not make it a recommended solution for known or suspected lamivudine-resistant HBV.
NIH — Hepatitis B Virus Infection: Adult and Adolescent Opportunistic Infections
25.Why must HBV treatment be preserved when ART is changed?
HBV suppression does not reliably eliminate the viral reservoir. Withdrawing HBV-active drugs can therefore cause rebound replication and potentially severe hepatitis. Before switching to an HIV regimen without HBV activity, arrange continued appropriate HBV treatment. Long-acting cabotegravir-rilpivirine does not replace HBV treatment. If HBV-active therapy must stop, closely monitor liver tests and HBV DNA so reactivation can be recognized before advanced clinical deterioration.
Apply it
A patient with suppressed HIV and undetectable HBV DNA on tenofovir-containing ART still needs an explicit HBV plan before changing to cabotegravir-rilpivirine.
Common pitfall: Waiting for jaundice is inadequate surveillance. Successful HIV suppression after the switch does not demonstrate safety for the separate chronic HBV infection.
NIH — Hepatitis B Virus Infection: Adult and Adolescent Opportunistic Infections
Antimicrobial Therapy9%
6.How should prolonged azole therapy be monitored for exposure and safety?
For triazole treatment of invasive aspergillosis, prolonged azole prophylaxis, or anticipated interactions, obtain therapeutic drug monitoring after steady state when appropriate to the agent. Voriconazole, itraconazole, and posaconazole suspension have clinically important exposure variability. Trough concentrations can help distinguish inadequate exposure from resistance or another cause of treatment failure and can identify excessive exposure contributing to toxicity. Review interacting medications alongside the antifungal concentration.
Apply it
During prolonged voriconazole treatment, assess trough exposure, liver tests, adverse symptoms, adherence, and interacting-drug concentrations when response or tolerance changes.
Common pitfall: One acceptable concentration does not establish adequate exposure throughout treatment. Evidence supporting routine monitoring is stronger for some formulations and agents than for others.
IDSA 2016 Clinical Practice Guideline Update for the Diagnosis and Management of Aspergillosis
26.Why are carbapenems preferred for invasive ESBL infection?
Extended-spectrum beta-lactamases hydrolyze many penicillins and cephalosporins, making apparent susceptibility an imperfect guide for some invasive infections. Carbapenems are preferred for invasive ESBL-producing Enterobacterales infections, including bacteremia. Piperacillin-tazobactam is not a dependable substitute simply because testing reports susceptibility. In critical illness or hypoalbuminemia, meropenem or imipenem is favored over ertapenem because altered protein binding and clearance can compromise ertapenem exposure.
Apply it
Choose a susceptible meropenem-based approach for ESBL E. coli bacteremia with shock and marked hypoalbuminemia.
Common pitfall: Evidence for selected bladder-infection treatments cannot be transferred automatically to bacteremia. Convenience and an initially susceptible report do not outweigh mechanism-specific and pharmacokinetic limitations.
IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
27.How does inducible AmpC change definitive therapy?
Some Enterobacterales can increase chromosomal AmpC production during treatment, permitting resistance despite initial ceftriaxone susceptibility. Enterobacter cloacae complex, Klebsiella aerogenes, and Citrobacter freundii are important examples. Cefepime is relatively stable against AmpC and has low induction potential, making it useful when susceptible and appropriate to the infection. Severity, source control, additional resistance mechanisms, and clinical response modify selection.
Apply it
For E. cloacae complex bacteremia, select an appropriate susceptible AmpC-stable agent rather than assuming initial ceftriaxone susceptibility will remain reliable.
Common pitfall: The susceptibility result describes the tested population at that moment. Inducible AmpC risk should not be generalized equally to every gram-negative species or every infection compartment.
IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
28.When is oral transition appropriate after resistant gram-negative bacteremia?
Oral transition requires a susceptible agent with adequate systemic and infection-site exposure, hemodynamic stability, reliable absorption, and appropriate source control. For selected ESBL bloodstream infections, susceptible trimethoprim-sulfamethoxazole or a fluoroquinolone can provide useful exposure. Nitrofurantoin and oral fosfomycin do not provide dependable serum exposure for bloodstream step-down treatment. The route alone is less important than achievable exposure and the patient's clinical trajectory.
Apply it
After drainage of urinary obstruction, consider susceptible oral trimethoprim-sulfamethoxazole for a stable patient who absorbs medication reliably.
Common pitfall: A urinary source does not make a bladder-concentrating drug sufficient for bacteremia. Conversely, resistance does not automatically require intravenous treatment throughout an otherwise appropriate course.
IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
29.Why do voriconazole interactions require drug-level monitoring?
Voriconazole inhibits CYP enzymes and can increase exposure to interacting drugs, including tacrolimus. Its variable, nonlinear pharmacokinetics also complicate prediction of antifungal exposure from dose alone. Monitor voriconazole and interacting-drug trough concentrations to balance efficacy against toxicity. Excessive tacrolimus exposure and inadequate antifungal exposure are distinct problems, so evaluating only one drug can miss the other. Monitoring must follow clinically important treatment changes.
Apply it
When adding voriconazole to tacrolimus, review the interaction, adjust therapy, and use serial concentrations to guide dosing.
Common pitfall: Stopping voriconazole reverses its inhibitory effect. A tacrolimus dose suitable during coadministration may subsequently produce inadequate exposure unless reassessed.
IDSA 2016 Clinical Practice Guideline Update for the Diagnosis and Management of Aspergillosis
30.Why do carbapenemase type and organism identity both matter?
KPC is a serine carbapenemase inhibited by selected newer inhibitors; NDM is a metallo-beta-lactamase not inhibited by avibactam, relebactam, or vaborbactam. Aztreonam resists NDM hydrolysis, while avibactam protects it from accompanying serine beta-lactamases. For invasive NDM-producing Enterobacterales infections, IDSA prefers aztreonam-avibactam or cefiderocol, guided by susceptibility. This cannot be generalized to metallo-beta-lactamase-producing Pseudomonas aeruginosa, for which cefiderocol is preferred.
Apply it
Distinguish NDM-producing Klebsiella pneumoniae from metallo-beta-lactamase-producing P. aeruginosa before applying organism-specific treatment recommendations.
Common pitfall: An enzyme name does not erase species-specific permeability, efflux, or target differences. Confirm organism, mechanism, infection site, and susceptibility together.
IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
31.Which treatment is preferred for initial nonfulminant C. difficile infection?
For an initial adult nonfulminant episode, the focused SHEA/IDSA guideline suggests fidaxomicin over a standard vancomycin course when resources permit, principally because fewer recurrences improve sustained response. Oral vancomycin remains an acceptable alternative. This recommendation assumes symptomatic infection rather than carriage and does not replace the separate approach to fulminant disease. Review unnecessary inciting antibiotics and patient factors associated with recurrence alongside drug selection.
Apply it
For confirmed first-episode diarrhea without hypotension, ileus, or megacolon, discuss fidaxomicin while recognizing oral vancomycin as an appropriate alternative.
Common pitfall: An acceptable alternative is not an incorrect treatment. The nonfulminant fidaxomicin preference should not be applied automatically to fulminant colitis.
SHEA/IDSA 2021 Focused Update for Clostridioides difficile Infection in Adults
Viral Diseases7%
32.How does the hepatitis B triple panel separate infection from immunity?
The triple panel measures HBsAg, anti-HBs, and total anti-HBc. HBsAg supports current infection, anti-HBs indicates a surface-antibody response, and anti-HBc indicates exposure to actual virus rather than vaccination alone. Negative HBsAg and anti-HBc with positive anti-HBs fit vaccine-associated immunity. Negative HBsAg with both antibodies positive fits resolved infection. Interpret the markers together because one result cannot establish the complete infection and immunity history.
Apply it
After a documented vaccine series, positive anti-HBs with negative HBsAg and anti-HBc supports vaccine-associated immunity.
Common pitfall: Vaccination does not generate core antibody. Surface antibody without the other markers cannot distinguish every possible history by itself.
33.How are acute and chronic hepatitis B distinguished?
HBsAg indicates current HBV infection but does not alone establish whether infection is acute or chronic. IgM anti-HBc supports recent infection in the appropriate clinical setting, whereas persistence of HBsAg for at least six months supports chronic infection. Interpret serology alongside previous results, symptoms, liver tests, and exposure history. IgM anti-HBc can also appear during severe flares or reactivation of chronic infection.
Apply it
A newly discovered positive HBsAg result requires historical and serologic clarification rather than an automatic label of acute hepatitis B.
Common pitfall: The date infection was discovered is not necessarily the date infection began. A single marker should not override documented longstanding HBsAg positivity or a compatible chronic-infection history.
34.What does an isolated hepatitis B core antibody mean?
Isolated total anti-HBc means HBsAg and anti-HBs are negative while core antibody is positive. Possibilities include resolved infection with waning surface antibody, a false-positive core result, or occult HBV. This is a pattern requiring interpretation rather than a single definitive diagnosis. Use exposure history, immune status, repeat testing when appropriate, and HBV DNA assessment when occult infection matters.
Apply it
Before chemotherapy, review previous results and risk factors, clarify possible occult or resolved infection, and incorporate the planned regimen into the prevention assessment.
Common pitfall: Isolated anti-HBc is not vaccine immunity. It also does not independently establish active hepatitis because biologically different states can produce the same pattern.
35.Which clinical and exposure findings should raise suspicion for measles?
Fever with cough, coryza, and conjunctivitis followed by a generalized maculopapular rash should raise suspicion, particularly after relevant travel or contact with a febrile rash illness. Vaccination history modifies probability but does not replace exposure assessment. Measles can spread before the rash makes the illness recognizable; patients are generally infectious from four days before through four days after rash onset.
Apply it
An adult with compatible symptoms after international travel requires immediate separation, airborne precautions, diagnostic assessment, and infection-prevention involvement.
Common pitfall: Do not wait for laboratory confirmation before acting on a plausible presentation. Immunocompromised patients may have atypical manifestations and prolonged infectiousness, so a conventional rash pattern is not universally present.
CDC — Measles Infection Prevention and Control in Healthcare Settings
Travel and Tropical Medicine5%
36.When should malaria microscopy be repeated?
A febrile traveler with relevant exposure requires urgent malaria assessment even after reported prophylaxis. One negative smear may miss low parasitemia, especially early in illness. If suspicion remains, repeat thick and thin smears every twelve to twenty-four hours until three sets have been examined. Testing must be available promptly enough to guide immediate care; slow send-out testing is insufficient as the sole strategy for potentially rapidly progressive disease.
Apply it
Arrange serial microscopy for a traveler with fever and thrombocytopenia when the first smear is negative but exposure remains strongly compatible.
Common pitfall: Prophylaxis reduces risk without excluding malaria. A single negative test is unsafe reassurance when no convincing alternative diagnosis explains the illness.
37.Why are malaria blood smears needed after a rapid test?
A rapid malaria test can accelerate recognition, but microscopy remains necessary to characterize infection and quantify parasitemia. Thick smears examine more blood and improve detection, while thin smears aid species identification and estimation of infected erythrocytes. Parasite burden and clinical organ dysfunction affect severity assessment. Rapid antigen results cannot provide all this information, may be falsely negative, and can remain positive after effective therapy.
Apply it
After a positive rapid antigen result, obtain thick and thin smears while prompt clinical management proceeds.
Common pitfall: Antigen positivity is unsuitable as the sole measure of clearance. A negative rapid result also cannot replace microscopy when the clinical probability remains substantial.
38.Why can remote Strongyloides exposure become dangerous after corticosteroids?
Strongyloides maintains infection through autoinfection, allowing remote exposure to remain relevant long after travel or migration. Corticosteroid-associated immune impairment can accelerate larval replication and migration, producing hyperinfection within the gastrointestinal-pulmonary cycle or dissemination beyond it. Severe disease can cause respiratory failure, intestinal injury, and recurrent gram-negative bacteremia. Eosinophilia may be absent during severe infection and should not determine whether evaluation proceeds.
Apply it
Investigate hyperinfection when a remotely exposed patient develops diarrhea, pulmonary infiltrates, and gram-negative bacteremia after high-dose corticosteroids.
Common pitfall: Recent travel is not required. A normal eosinophil count is particularly unreliable reassurance during corticosteroid-associated severe strongyloidiasis.
Fungi5%
39.How should candidemia treatment be started and its duration determined?
An echinocandin is recommended initially for most nonneutropenic adults, especially with critical illness or possible azole resistance. Fluconazole is an alternative for selected stable patients unlikely to have a resistant isolate. Obtain follow-up cultures daily or every other day. Without metastatic complications, treat for at least two weeks after documented clearance and resolution of attributable symptoms; neutropenic patients additionally require neutrophil recovery.
Apply it
If cultures clear Friday after treatment began Monday, calculate the uncomplicated minimum course from clearance and confirm symptom resolution.
Common pitfall: Persistent cultures require source and complication reassessment. Endocarditis or another deep focus requires a different duration, and fluconazole transition requires stability, susceptibility, and clearance.
40.How does coccidioidal meningitis change antifungal duration?
Endemic residence or travel is essential context for coccidioidomycosis. Persistent or worsening headache, altered mental status, unexplained vomiting, or focal neurologic findings warrant CNS assessment and CSF evaluation after appropriate imaging. IDSA recommends fluconazole 400–1200 mg daily initially for most adults with coccidioidal meningitis and normal renal function, followed by lifelong azole treatment. Clinical improvement does not establish eradication or justify stopping suppression.
Apply it
Persistent headache after pulmonary coccidioidomycosis warrants evaluation for meningitis rather than attribution to routine convalescence.
Common pitfall: The treatment boundary differs from mild uncomplicated pulmonary infection, where observation may be appropriate. Neurologic deterioration during treatment requires reassessment for complications, including hydrocephalus.
IDSA 2016 Clinical Practice Guideline for the Treatment of Coccidioidomycosis
41.How should suspected pulmonary aspergillosis be assessed during mold-active prophylaxis?
Prolonged neutropenia with new pulmonary nodules warrants CT and directed investigation. Serum and BAL galactomannan support diagnosis in appropriate hematologic populations, but routine serum screening is not recommended during mold-active prophylaxis; BAL testing can remain useful. Suspected breakthrough disease requires prompt sampling, review of prior exposure and azole concentrations, assessment for resistance or another mold, and generally an empiric change to another antifungal class.
Apply it
For new nodules during posaconazole prophylaxis, pursue BAL or biopsy when feasible and assess drug exposure rather than automatically applying ordinary primary therapy.
Common pitfall: Negative serum galactomannan during prophylaxis does not exclude disease. Adequate azole exposure increases concern for resistance or an alternative mold.
IDSA 2016 Clinical Practice Guideline Update for the Diagnosis and Management of Aspergillosis
Immunocompromised Host (Non-HIV Infection)5%
42.Which cancer-treatment risks support antimicrobial prophylaxis?
In cancer-related immunosuppression, infection risk depends on neutrophil depth and duration. Expected profound, protracted neutropenia, defined by ASCO/IDSA as fewer than one hundred neutrophils per microliter for more than seven days, supports antibacterial and antifungal prophylaxis. Other major risk factors can also justify prevention. HSV-seropositive patients undergoing allogeneic hematopoietic stem-cell transplantation or leukemia induction should receive nucleoside-analogue prophylaxis such as acyclovir.
Apply it
Plan antibacterial and antifungal prophylaxis before leukemia induction expected to cause an absolute neutrophil count below 100 per microliter for ten days, and assess HSV serostatus.
Common pitfall: One low count does not characterize duration. Prophylaxis does not make new fever safe to observe without prompt evaluation and treatment.
ASCO/IDSA — Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression
43.How should suspected pulmonary mold infection be diagnosed in a transplant recipient?
For suspected invasive pulmonary aspergillosis after solid-organ transplantation, obtain chest CT and pursue BAL when feasible. Send specimens for culture, cytology, and appropriate nonculture testing. Serum galactomannan is not recommended for screening solid-organ transplant recipients, and a negative result cannot close the evaluation. Peripheral nodules may have low BAL yield, making targeted biopsy valuable. Submit adequate tissue for simultaneous histopathology and culture.
Apply it
A kidney transplant recipient with peripheral nodules despite negative serum galactomannan needs directed respiratory sampling or lesion biopsy.
Common pitfall: Biomarker performance in hematologic malignancy cannot be assumed in transplantation. Severe hypoxemia or bleeding risk may preclude BAL and require another feasible diagnostic approach.
IDSA 2016 Clinical Practice Guideline Update for the Diagnosis and Management of Aspergillosis
44.Which abdominal Candida findings indicate infection after transplantation?
In a transplant recipient with an anastomotic leak or postoperative collection, interpret Candida according to specimen quality and clinical findings. Yeast from a normally sterile operative specimen or drain placed within twenty-four hours supports intra-abdominal candidiasis when infection is present. Cultures from older drains do not reliably distinguish infection from colonization. Blood cultures may remain negative. Treatment requires source control plus appropriate antifungal therapy.
Apply it
Candida from a newly placed drain in an infected postoperative collection supports treatment alongside correction of the anatomical source.
Common pitfall: Negative blood cultures do not exclude deep abdominal candidiasis. Growth from a longstanding drain alone does not establish invasion; duration depends on source control and response.
Vaccinations4%
45.Which conditions contraindicate MMR vaccination?
MMR contains live attenuated viruses, so pregnancy and severe immunodeficiency are major contraindications because vaccine-organism replication may create unacceptable risk. A severe allergic reaction to a previous dose or component is another contraindication. Mild intercurrent illness is not a contraindication; moderate or severe acute illness is generally a precaution. Distinguish recipient-specific risks from circumstances such as breastfeeding or having a pregnant household contact.
Apply it
Defer MMR in a pregnant adult without rubella immunity and plan postpartum vaccination. Mild rhinorrhea alone should not prevent vaccination of an otherwise eligible adult.
Common pitfall: A precaution calls for assessment of timing and benefit rather than automatic permanent avoidance. Neither household pregnancy nor breastfeeding alone establishes the recipient's pregnancy contraindication.
46.How should MMR and varicella vaccination be coordinated?
Administer MMR and varicella vaccine on the same day or separate them by at least twenty-eight days. When different injectable live vaccines are administered on separate days too close together, the response to the later vaccine can be impaired. This rule concerns the interaction between live-vaccine responses and does not create a requirement to separate every combination of vaccines.
Apply it
For an eligible adult needing both vaccines, same-day administration avoids a return visit and an interval error. If MMR was given yesterday, schedule varicella vaccine at least twenty-eight days after that dose.
Common pitfall: Do not shorten the interval by applying a routine four-day grace period between different injectable live vaccines. Confirm live-vaccine eligibility before applying the scheduling rule.
Infection Prevention and Control5%
47.How should suspected measles be isolated?
Suspected measles requires prompt airborne precautions because infectious particles can remain suspended beyond close droplet range. Place the patient in an airborne infection isolation room and use appropriate respiratory protection, including a fit-tested N95 or equivalent for entering personnel. Mask the patient for necessary transport and limit movement. Begin precautions on suspicion while testing, infection-prevention involvement, and public health notification proceed.
Apply it
Immediately separate an unvaccinated traveler with fever, cough, conjunctivitis, and generalized rash and arrange airborne isolation.
Common pitfall: A surgical mask on staff does not substitute for an appropriate respirator. The patient's transport mask provides source control but does not make shared-room placement acceptable.
CDC — Measles Infection Prevention and Control in Healthcare Settings
48.Why does C. difficile require sporicidal environmental cleaning?
C. difficile produces persistent spores that contaminate rooms, shared equipment, and high-touch surfaces. Prevention includes daily and terminal cleaning with an appropriate sporicidal agent, contact precautions, and equipment management. Ordinary cleaning products are not interchangeable with products effective against spores. Follow the product instructions, including required contact time. Environmental control addresses the reservoir while antimicrobial stewardship reduces antibiotic-associated susceptibility.
Apply it
For ongoing ward transmission, review disinfectant choice, contact time, daily and discharge cleaning, and shared equipment handling.
Common pitfall: Visible cleanliness does not establish effective spore control. A suitable product used for insufficient contact time can undermine an otherwise appropriate cleaning policy.
49.How does appropriate C. difficile testing support prevention?
Test patients with clinically significant unexplained diarrhea rather than asymptomatic carriers. Review laxatives and alternative causes, and follow the institutional diagnostic algorithm. Molecular detection can identify toxigenic organisms without proving toxin-mediated illness, so testing the wrong population inflates apparent disease and encourages unnecessary treatment. Avoid tests of cure after recovery because results may remain positive. Begin appropriate precautions promptly when infection is suspected.
Apply it
Review a laxative-related explanation before testing one patient, while promptly isolating and evaluating another with unexplained new diarrhea.
Common pitfall: A positive molecular assay cannot correct an inappropriate testing indication. Persistent positivity after recovery may represent carriage rather than a reason for additional treatment.
Internal Medicine and Non-Infectious Syndromes18%
50.Which vasopressor is first line for septic shock?
Norepinephrine is the usual first-line vasopressor for septic shock because it restores vascular tone and arterial pressure with a more favorable arrhythmia profile than dopamine. Persistent hypotension requires prompt support while infection treatment and source evaluation proceed. Vasopressin can be added as norepinephrine requirements escalate. Significant concomitant cardiac dysfunction changes the physiological assessment and can affect selection, including consideration of epinephrine.
Apply it
For persistent vasodilatory hypotension after initial fluids without major cardiac dysfunction, begin norepinephrine while reassessing perfusion.
Common pitfall: Vasopressor selection does not replace assessment of myocardial function or fluid responsiveness. Repeated indiscriminate fluid boluses can worsen overload without correcting vasodilation.
51.Why is source control urgent in sepsis?
An abscess, infected obstruction, necrotic tissue, or another uncontrolled anatomical focus can sustain infection despite active antibiotics. Source control drains or removes that nidus. The 2026 Surviving Sepsis Campaign suggests early rather than late intervention, ideally within six hours of diagnosing sepsis or septic shock requiring source control. Coordinate resuscitation and intervention promptly; antibiotics support but do not replace the necessary procedure.
Apply it
Arrange urgent decompression for an infected obstructed collecting system while giving active antibiotics and resuscitation.
Common pitfall: Broader antibiotics cannot reliably compensate for obstruction or an undrained collection. The conditional timing recommendation requires a feasible intervention appropriate to the anatomy and clinical circumstances.
52.How should antibiotic timing reflect sepsis probability and shock?
The 2026 campaign recommends immediate antimicrobials, ideally within one hour, for possible, probable, or definite septic shock and for probable or definite sepsis without shock. Possible sepsis without shock allows a time-limited rapid investigation, with treatment within three hours if concern persists. Low infection likelihood without shock can support close monitoring without immediate antibiotics. Probability and physiological danger determine urgency.
Apply it
Give immediate empiric treatment for suspected infection with shock, while rapidly investigating competing explanations in a stable patient with possible sepsis.
Common pitfall: Do not apply the diagnostic window for stable uncertain illness to shock. An isolated inflammatory marker does not automatically establish probable infection or mandate antibiotics.
53.How should additional fluid responsiveness be assessed?
After initial resuscitation, guide additional fluid through repeated assessment rather than static pressure alone. Dynamic measures examine changes in stroke volume or related variables during passive leg raise or a fluid challenge. A positive response suggests preload responsiveness; absent response makes further fluid less likely to improve output. Integrate perfusion needs, respiratory status, and fluid tolerance because responsiveness does not establish that another bolus is necessary or safe.
Apply it
Use passive leg raise with stroke-volume assessment when hypotension persists alongside developing pulmonary edema.
Common pitfall: A single central venous pressure is not a reliable substitute for dynamic assessment. Even a responsive circulation may not tolerate more fluid when congestion is important.
54.Which findings establish the clinical framework for ARDS?
ARDS requires an acute predisposing risk factor such as pneumonia, nonpulmonary infection, aspiration, trauma, transfusion, or shock. Hypoxemic respiratory failure must arise or worsen within one week of the estimated onset of that risk factor or new or worsening respiratory symptoms. Require bilateral imaging abnormalities not fully explained by effusions, atelectasis, or nodules. Edema must not be primarily cardiogenic or due to fluid overload, and gas-exchange impairment must not be primarily attributable to atelectasis.
Apply it
Three days after pneumonia begins, bilateral opacities and a PaO2/FiO2 ratio of 160 on PEEP 8 support moderate intubated ARDS when the remaining criteria hold.
Common pitfall: Neither bilateral opacities nor a low ratio independently establishes ARDS. Qualifying oxygenation and respiratory-support criteria must also hold.
Global Definition Consensus Conference — ARDS Diagnostic Criteria
55.How is the PaO2-to-FiO2 ratio interpreted in intubated ARDS?
Divide arterial oxygen tension by inspired oxygen expressed as a fraction. With other criteria met and PEEP at least 5 cm H2O, ratios above 200 through 300 indicate mild disease; above 100 through 200 indicate moderate disease; and 100 or less indicate severe disease. Interpret measurements under stable conditions rather than immediately after changes in oxygen delivery or positioning.
Apply it
PaO2 80 mmHg on FiO2 0.50 gives 80/0.50 = 160 mmHg, indicating moderate intubated ARDS with qualifying support.
Common pitfall: Using 50 instead of 0.50 produces a meaningless ratio. A mathematically correct ratio still requires the broader timing, imaging, edema-origin, and support criteria.
Global Definition Consensus Conference — ARDS Diagnostic Criteria
56.When can a nonintubated patient meet the global ARDS definition?
With the remaining criteria satisfied, nonintubated ARDS requires PaO2/FiO2 at most 300 mmHg or SpO2/FiO2 at most 315 while receiving high-flow nasal oxygen at least 30 L/min or NIV/CPAP with expiratory pressure at least 5 cm H2O. Use the saturation-based ratio only when SpO2 is 97% or lower. Support and oxygenation requirements must be assessed together.
Apply it
On high-flow oxygen at 40 L/min, SpO2 92% with FiO2 0.50 gives a saturation ratio of 184 and meets the oxygenation threshold.
Common pitfall: Intubation is not mandatory. Saturation above 97% or inadequately specified respiratory support prevents straightforward application of these particular criteria.
Global Definition Consensus Conference — ARDS Diagnostic Criteria
57.Which pattern should raise suspicion for adult HLH?
HLH is a hyperinflammatory syndrome involving dysregulated immune activation. Persistent fever, splenomegaly, cytopenias, marked ferritin elevation, hypertriglyceridemia, and low fibrinogen form a concerning pattern, especially with progressive organ dysfunction despite appropriate antimicrobial care. Infection, malignancy, and autoimmune inflammation can trigger adult disease. Ferritin is a clue rather than a standalone diagnosis, and infection can coexist with HLH.
Apply it
Investigate HLH and triggers such as occult lymphoma when fever, falling counts, splenomegaly, and low fibrinogen persist despite appropriate infection treatment.
Common pitfall: Extreme ferritin is not specific in adults. Finding an infection does not exclude a simultaneously triggered inflammatory syndrome or remove the need to assess the full pattern.
58.How should HLH diagnostic criteria be applied in adults?
HLH-2004 permits diagnosis through a compatible molecular diagnosis or five of eight criteria: fever, splenomegaly, qualifying cytopenias in at least two lineages, fasting triglycerides at least 265 mg/dL and/or fibrinogen at most 1.5 g/L, tissue hemophagocytosis, low or absent NK-cell activity, ferritin at least 500 micrograms/L, and soluble CD25 at least 2400 U/mL. Cytopenia thresholds are hemoglobin below 9 g/dL, platelets below 100 × 10^9/L, or neutrophils below 1.0 × 10^9/L.
Apply it
Count qualifying anemia and thrombocytopenia as one cytopenia criterion; triglyceride and fibrinogen abnormalities likewise constitute one criterion.
Common pitfall: This pediatric-derived framework is not formally validated in adults. Hemophagocytosis is neither universally present nor independently diagnostic. Clinical deterioration can require decisions before specialized results return.
59.How does heat stroke differ from uncomplicated heat exhaustion?
Heat stroke combines severe heat illness with CNS dysfunction such as confusion, seizures, or coma and requires emergency cooling and medical care. Skin may be dry or sweaty, particularly during exertional illness. Move the patient from heat, remove excess clothing, and begin rapid active cooling while arranging emergency support. Failure of heat regulation makes cooling central rather than treating the temperature as ordinary infectious fever.
Apply it
A confused runner with marked hyperthermia and ongoing sweating requires immediate cooling and emergency support.
Common pitfall: Waiting for dry skin, laboratory results, or an infectious diagnosis delays essential care. Continued sweating does not exclude exertional heat stroke.
60.When should exertional rhabdomyolysis be suspected?
Prolonged exertion and heat stress can cause skeletal muscle breakdown, releasing intracellular contents and creating risks of kidney injury and dangerous electrolyte abnormalities. Muscle pain, weakness, or dark urine after exertion warrants urgent assessment, including creatine kinase and kidney function. Symptoms overlap with dehydration, so assuming simple fluid depletion can miss substantial injury. Rhabdomyolysis can accompany heat stroke without requiring the same CNS dysfunction.
Apply it
Stop exertion and urgently assess severe muscle pain, weakness, and cola-colored urine after strenuous work in heat.
Common pitfall: The complete symptom combination need not be present. Absence of visible pigmenturia does not exclude important muscle breakdown or its renal and electrolyte complications.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Prioritize Bacterial Diseases, HIV, and Internal Medicine and Non-Infectious Syndromes while deliberately covering all ten official domains.
- Distinguish colonization, latent infection, active disease, and inflammatory mimics before selecting treatment.
- Interpret diagnostic results through exposure, timing, specimen quality, host factors, and the biological question each assay answers.
- Connect antimicrobial selection to organism, resistance mechanism, infection compartment, achievable exposure, interactions, toxicity monitoring, and source control.
- Coordinate rapid HIV treatment with baseline resistance testing, opportunistic-infection timing exceptions, and preservation of HBV treatment.
- Recognize interventions beyond antimicrobials, including drainage, decompression, intracranial-pressure management, respiratory support, and rapid cooling.
- Use the complete ABIM outline to extend this selective foundation to additional organisms, syndromes, immunodeficiencies, pharmacology, and prevention.
A practical preparation plan
1. Map the complete outline
Use ABIM's January 2026 certification PDF as the master scope. Mark each subsection as established knowledge, uncertain knowledge, or an unstudied area. These concepts provide selected decision anchors.
2. Explain diagnosis-to-action reasoning
For each syndrome, identify the decisive exposure or host clue, the appropriate specimen or assay, the meaning of a negative result, and the action that follows.
3. Study treatment boundaries
For each treatment, record infection site, resistance mechanism, severity, organ function, interactions, toxicity monitoring, and source-control requirements. Explain why competing options are less appropriate.
4. Work the clinical drills
Choose an answer before reading the explanation. Classify errors as syndrome recognition, test interpretation, pharmacology, prevention, or urgency, then restate the decisive cue.
5. Rehearse calculations and exceptions
Practise oxygenation ratios, fourfold titer changes, high-risk tick criteria, live-vaccine spacing, cryptococcal pressure management and ART timing, and preservation of HBV therapy during ART changes.
6. Expand and reassess
Use spaced recall, then return to weak official-outline subsections. Recheck primary clinical guidance in evolving treatment areas and current ABIM candidate information before the examination.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABIM — Blueprints
- Infectious Disease Blueprint — Certification Examination (CERT), January 2026
- ABIM — Register, Prepare and Take Your Subspecialty Certification Exam: Infectious Disease
- ABIM — Infectious Disease Certification Policies
- ABIM — Expanded Blueprints
- IDSA 2019 Guideline for the Management of Asymptomatic Bacteriuria
- CDC — Clinical and Laboratory Diagnosis for Tuberculosis
- CDC — Syphilis: STI Treatment Guidelines
- AAN/ACR/IDSA 2020 Guidelines for Lyme Disease
- CDC — Clinical Signs and Symptoms of Ehrlichiosis
- NIH — Early, Acute and Recent HIV Infection
- NIH — Cryptococcosis: Adult and Adolescent Opportunistic Infections
- NIH — Hepatitis B Virus Infection: Adult and Adolescent Opportunistic Infections
- IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
- SHEA/IDSA 2021 Focused Update for Clostridioides difficile Infection in Adults
- CDC — Clinical Testing and Diagnosis for Hepatitis B
- CDC — Evaluation and Diagnosis of Malaria
- CDC — Clinical Overview of Strongyloides
- IDSA 2016 Guideline for the Management of Candidiasis
- ASCO/IDSA — Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression
- CDC — Vaccine Contraindications and Precautions
- CDC — Measles Infection Prevention and Control in Healthcare Settings
- CDC — C. diff Infection Prevention in Acute Care Facilities
- Surviving Sepsis Campaign — Adult Guidelines, 2026
- Global Definition Consensus Conference — ARDS Diagnostic Criteria
- Recommendations for the Management of Hemophagocytic Lymphohistiocytosis in Adults — 2019 Blood First Edition Manuscript, Mirrored Copy
- CDC/NIOSH — Heat-Related Illnesses
- IDSA/ESCMID 2026 Consensus Statements on Staphylococcus aureus Bacteremia: Risk Stratification, Diagnostic Evaluation, and Management of Adults and Children
- IDSA 2016 Clinical Practice Guideline Update for the Diagnosis and Management of Aspergillosis
- IDSA 2016 Clinical Practice Guideline for the Treatment of Coccidioidomycosis
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.